StockData

Amphastar Pharmaceuticals, Inc. (AMPH) stock

AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3013% below fair value
$29.10−0.07 (-0.24%)

Close on Nov 17, 2026Market cap $1.24BP/E 17.1Yield –

Amphastar Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Amphastar Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $730.02M, up 1.0% year over year. For fiscal 2025 it was $719.89M, down 1.7% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is $731.97M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$719.89M-1.7%
FY2024Dec 31, 2024$731.97M+13.6%
FY2023Dec 31, 2023$644.40M+29.1%
FY2022Dec 31, 2022$498.99M+14.0%
FY2021Dec 31, 2021$437.77M+25.1%
FY2020Dec 31, 2020$349.85M+8.5%
FY2019Dec 31, 2019$322.36M+9.4%
FY2018Dec 31, 2018$294.67M+22.7%
FY2017Dec 31, 2017$240.18M-5.9%
FY2016Dec 31, 2016$255.17M+1.4%
FY2015Dec 31, 2015$251.52M+19.5%
FY2014Dec 31, 2014$210.46M-8.4%
FY2013Dec 31, 2013$229.68M+12.4%
FY2012Dec 31, 2012$204.32M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$183.90M+5.4%
Q1 FY2026Mar 31, 2026$171.17M+0.4%
Q4 FY2025Dec 31, 2025$183.11M-1.8%
Q3 FY2025Sep 30, 2025$191.84M+0.3%
Q2 FY2025Jun 30, 2025$174.41M-4.4%
Q1 FY2025Mar 31, 2025$170.53M-0.8%
Q4 FY2024Dec 31, 2024$186.52M+4.7%
Q3 FY2024Sep 30, 2024$191.21M+5.9%
Q2 FY2024Jun 30, 2024$182.39M+25.2%
Q1 FY2024Mar 31, 2024$171.84M+22.7%
Q4 FY2023Dec 31, 2023$178.11M+31.9%
Q3 FY2023Sep 30, 2023$180.56M+50.3%
Q2 FY2023Jun 30, 2023$145.71M+18.0%
Q1 FY2023Mar 31, 2023$140.02M+16.3%
Q4 FY2022Dec 31, 2022$135.02M+11.7%
Q3 FY2022Sep 30, 2022$120.13M+7.1%
Q2 FY2022Jun 30, 2022$123.47M+21.4%
Q1 FY2022Mar 31, 2022$120.37M+16.8%
Q4 FY2021Dec 31, 2021$120.89M+26.0%
Q3 FY2021Sep 30, 2021$112.20M+34.5%
Q2 FY2021Jun 30, 2021$101.66M+18.5%
Q1 FY2021Mar 31, 2021$103.02M+21.6%
Q4 FY2020Dec 31, 2020$95.92M+15.0%
Q3 FY2020Sep 30, 2020$83.43M+4.1%
Q2 FY2020Jun 30, 2020$85.81M+8.6%
Q1 FY2020Mar 31, 2020$84.69M+6.1%
Q4 FY2019Dec 31, 2019$83.38M-7.0%
Q3 FY2019Sep 30, 2019$80.14M+6.1%
Q2 FY2019Jun 30, 2019$79.05M+11.3%
Q1 FY2019Mar 31, 2019$79.79M+36.6%
Q4 FY2018Dec 31, 2018$89.69M+48.5%
Q3 FY2018Sep 30, 2018$75.54M+30.4%
Q2 FY2018Jun 30, 2018$71.04M+9.0%
Q1 FY2018Mar 31, 2018$58.39M+3.0%
Q4 FY2017Dec 31, 2017$60.40M-4.9%
Q3 FY2017Sep 30, 2017$57.92M-9.8%
Q2 FY2017Jun 30, 2017$65.19M–
Q1 FY2017Mar 31, 2017$56.67M–
Q4 FY2016Dec 31, 2016$63.54M–
Q3 FY2016Sep 30, 2016$64.22M–

More Amphastar Pharmaceuticals figures

See a number that looks wrong?